aTyr Pharma (NASDAQ:ATYR) Announces Earnings Results, Beats Expectations By $0.01 EPS

aTyr Pharma (NASDAQ:ATYR) released its quarterly earnings results on Friday. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01, FiscalAI reports. The business had revenue of $189.56 million for the quarter.

aTyr Pharma Price Performance

Shares of ATYR stock traded up $0.01 on Friday, reaching $0.51. 355,761 shares of the stock were exchanged, compared to its average volume of 1,115,501. aTyr Pharma has a one year low of $0.40 and a one year high of $6.50. The stock has a market cap of $50.14 million, a PE ratio of -0.70 and a beta of 0.54. The stock has a 50 day moving average price of $0.51 and a 200 day moving average price of $0.70.

Analysts Set New Price Targets

A number of equities analysts have commented on ATYR shares. Freedom Capital raised aTyr Pharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 20th. Weiss Ratings lowered aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. Finally, Wall Street Zen raised aTyr Pharma from a “sell” rating to a “hold” rating in a report on Sunday, July 12th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $17.00.

Insider Transactions at aTyr Pharma

In other news, Director Paul Schimmel purchased 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were acquired at an average price of $0.50 per share, for a total transaction of $50,000.00. Following the completion of the acquisition, the director directly owned 779,143 shares in the company, valued at approximately $389,571.50. The trade was a 14.72% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 5.75% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ATYR. Bank of America Corp DE grew its position in shares of aTyr Pharma by 319.6% during the 3rd quarter. Bank of America Corp DE now owns 177,671 shares of the company’s stock worth $128,000 after buying an additional 135,325 shares during the period. Squarepoint Ops LLC acquired a new position in aTyr Pharma in the third quarter valued at approximately $90,000. JPMorgan Chase & Co. boosted its stake in aTyr Pharma by 157.4% in the third quarter. JPMorgan Chase & Co. now owns 105,817 shares of the company’s stock valued at $76,000 after acquiring an additional 64,710 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in aTyr Pharma during the 2nd quarter worth $99,000. Finally, Raymond James Financial Inc. grew its holdings in aTyr Pharma by 79.3% during the 2nd quarter. Raymond James Financial Inc. now owns 24,839 shares of the company’s stock worth $126,000 after acquiring an additional 10,989 shares during the period. 61.72% of the stock is currently owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.